Ipsen reported third-quarter sales of EUR 1.17 billion, up 28% from the prior-year period. Management raised its 2026 guidance for total sales growth to around 23% at constant exchange rates (previously 20%) and raised core operating margin to around 39% (up from 37%).
Ipsen has a sound financial structure and strong cash generation, which allows it to further develop and expand its pipeline.
Many of Ipsen’s products are facing competitive pressures from lower-priced generics.
Metric | IPN | JAZZ | UCB |
|---|---|---|---|
Price/Earnings (Normalized) | 13.49 | 24.11 | 24.69 |
Price/Book Value | 2.93 | 3.68 | 4.82 |
Price/Sales | 3.23 | 3.40 | 6.71 |
Price/Cash Flow | 10.55 | 8.62 | 23.53 |
Metric | IPN | JAZZ | UCB |
|---|---|---|---|
Quick Ratio | 1.76 | 1.47 | 0.82 |
Current Ratio | 1.97 | 1.82 | 1.20 |
Interest Coverage | 15.24 | 2.55 | 27.73 |
Metric | IPN | JAZZ | UCB |
|---|---|---|---|
Return on Assets (Normalized) | 15.69% | 8.51% | 13.57% |
Return on Equity (Normalized) | 25.09% | 22.61% | 23.59% |
Return on Invested Capital (Normalized) | 21.65% | 11.63% | 19.03% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|<bL%k?C> | LOCK|<Svq | $71B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|#n?Z>k?P | LOCK|sDKsH | $51B | |||
| Haleon PLC ADR HLN | LOCK|$!?#!$t | LOCK|mK> | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|p?M<^XT< | LOCK|@s | $34B | |||
| Viatris Inc VTRS | LOCK|@y^&LW | LOCK|V@T | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|@! | LOCK|HvX | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|L<?#w#C | LOCK|YN% | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|^#@<W^ | LOCK|Lb% | $5B | |||
| Perrigo Co PLC PRGO | LOCK|^kw>X> | LOCK|<m | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|yY##>P | LOCK|<ZH# | $2B |
United States